RxSight signs Alcon lens deal worth up to $200 million
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
RxSight announced a non-exclusive collaboration with Alcon worth up to $200 million to develop adjustable presbyopia-correcting intraocular lenses, letting the company expand beyond cataract surgery. Second-quarter product sales fell and gross margins declined. Twelve firms carry a consensus target of USD 8.17, with the next earnings report expected on November 4, 2026.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.